11
NEWS
Action to tackle rise in T2D
Cases of younger people being diagnosed with Type 2 diabetes in the UK are rising to
'alarming levels', a charity has warned.
Type 2 diabetes has historically been associated with older people, but cases among
under 40s have been on the rise in recent years and are now increasing at a faster rate
than among over 40s. A new report, Reverse the Trend, published by Diabetes UK for Type
2 Diabetes Prevention Week (which took place May 20-26), reveals there was an almost
40% increase in the number of people under the age of 40 living with a diagnosis of Type 2
diabetes between 2016-17 and 2022-23. The charity estimates there are now almost 168,000
people under 40 with the condition in the UK, a rise of more than 47,000 since 2016-17, and
says the UK Government faces 'a generational opportunity' to tackle the crisis with a range
of measures, including addressing the factors causing obesity and health inequalities.
Furthermore, many thousands more young adults are likely to be living with
undiagnosed Type 2 diabetes: a recent report by the Office for National Statistics estimated
that 50% of those aged 16-44 with Type 2 diabetes had not yet received a diagnosis.
As part of Type 2 Diabetes Prevention Week, Diabetes UK is urging people to check their
risk of the condition by using the charity's free, online Know Your Risk tool.
www.riskscore.diabetes.org.uk/start
Click the pick to
download the full
report as a PDF.
CamAPS FDA approval
CamDiab has received authorisation
from the Food and Drug
Administration (FDA) in the US
for its advanced adaptive hybrid
closed-loop app, CamAPS FX, as an
'interoperable automated glycaemic
controller device'
The Android app helps to manage
glucose levels in people with Type
1 diabetes by allowing a compatible
insulin pump and a compatible
continuous glucose monitor to 'talk
to each other', creating an artificial
pancreas.
The CamAPS FX closed loop
algorithm has been extensively
tested in clinical trials and has
already been CE-marked for use
in the UK and the EU. CamAPS FX
creator Roman Hovorka, Professor
of Metabolic Technology at the
Institute of Metabolic Science and
Department of Paediatrics at the
University of Cambridge, where the
technology was developed, said,
"Randomised clinical trials have
shown a significant increase in time
in range and a reduction in HbA1c
without increasing the risk of low
glucose levels, as well as improved
well-being."
Medtronic, Arecor to develop new insulin
Arecor and Medtronic have partnered
to create a new type of insulin that
would allow for the use of new
insulin pump designs, which would
sit under the skin, rather than on the
surface. The collaboration aims to
develop a novel, high-concentration,
thermostable insulin for use by
Medtronic in a next-generation
pump. A new insulin of this kind
could minimize the need for pump
maintenance interventions and
expand utility for physicians while
saving costs.
Gary Dulak, senior director of
new venture programs at Medtronic
Diabetes explained that, "With an
implantable insulin pump system,
insulin delivery is targeted for
direct absorption by the liver via
the implantable pump. Arecor and
Medtronic's new insulin remains at an
early stage in development and would
still require clinical trials.